High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients. by Abdullah, Laila et al.
INTRODUCTION
Alzheimer’s Disease (AD) is character-
ized clinically by progressive cognitive
impairment and pathologically by the
presence of β-amyloid (Aβ) plaques and
neurofibrillary tangles. The etiology of
the rare early-onset familial form of AD
has been attributed to mutations in the
genes for amyloid precursor protein
(APP) and presenilin 1/2 (PS1/2). These
mutations lead to aberrant proteolytic
processing by the β- and γ-secretases, fol-
lowed by increased production of Aβ1-42
and Aβ1-40 fragments (1). Pathogenesis of
the common late-onset AD (LOAD) re-
mains unclear, although it is postulated
that either excessive Aβ production or re-
duced Aβ clearance may result in the ac-
cumulation and deposition of Aβ in the
brain. Therefore, evaluation of the under-
lying mechanisms with respect to Aβ
clearance from the brain into cere-
brospinal fluid and blood remains an
area of active investigation.
Despite uncertainty regarding the ori-
gin of Aβ in the blood, several studies
provide strong evidence for the associa-
tion of altered blood Aβ levels with AD
risk, onset, and progression (2–6).
Among AD patients, an initial increase in
blood Aβ1-42 is followed by a decrease (2),
and an increase in Aβ1-42 over time was
shown to be a significant predictor of
conversion to mild cognitive impairment
or AD (5). More recently, Aβ1-42 was
shown to be higher in patients with mild
cognitive impairment compared with
both AD patients and controls (7). These
findings suggest that alterations in blood
Aβ levels may be a reflection of brain Aβ
pathology.
Evidence for a significant heredity
component to blood Aβ1-42 and Aβ1-40 lev-
els comes from family-based genetic link-
age analyses pointing to markers on
chromosome 10 (8) and an increase in
plasma Aβ1-42 among the first-degree
family members of patients with LOAD
has also been observed (9). Mutations in
PS1/2 genes are shown to influence
blood Aβ1-42 levels in early-onset AD pa-
tients and their presymptomatic relatives
(10,11). However, governance of elevated
blood Aβ1-42 levels in the first-degree rel-
atives of LOAD patients remains unex-
plained by these genes (9). Familial clus-
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tering in LOAD is attributed to an in-
creased occurrence of the apolipoprotein E
(APOE) ε4 allele, but it accounts for only
13.7% of the AD incidence (12–14), and
no relationship of blood Aβ1-42 with ε4
carrier status has been observed in the
first-degree relatives of LOAD patients
(9). Thus, a possibility remains for pres-
ence of other factors that may impact
blood Aβ in the first-degree relatives of
LOAD patients.
Vascular risk factors are shown to play
a significant role in the etiology of LOAD
(15). Several studies provide strong evi-
dence that high blood pressure and hy-
percholesterolemia are associated with
an increased risk of dementia, including
AD (16–19). Therefore, we hypothesize
that these vascular risk factors may im-
pact blood Aβ levels. Support for this hy-
pothesis comes from a study of two inde-
pendent mouse models of hypertension,
which demonstrated that chronic hyper-
tension results in increased brain Aβ
deposition in the cortex and hippocam-
pus attributable to increased permeabil-
ity of the blood-brain barrier. This find-
ing suggests that chronic hypertension
may be responsible for brain Aβ deposi-
tion by either reducing brain Aβ clear-
ance or allowing entrance of peripheral
Aβ into the brain (20). Cholesterol clear-
ance pathways are also fundamental to
AD pathophysiology, and a key receptor
for lipoprotein, low-density lipoprotein
(LDL)-receptor–related protein 1, has
been shown to mediate Aβ clearance
from the brain via its transport across the
blood-brain barrier. Alteration in expres-
sion of LDL-receptor–related protein 1
and a receptor for advanced glycation
end products in AD mouse models is
shown to result in dysregulation of Aβ
efflux/influx across the blood-brain bar-
rier, further enhancing brain Aβ deposi-
tion (21). These findings suggest that
chronic hypertension and a dysfunction
in cholesterol efflux pathways may dis-
rupt brain Aβ homeostasis.
It is widely accepted that the AD pro-
cess begins decades before the presence
of clinical symptoms, and the relevant
peripheral Aβ levels associated with AD
pathology may be those observed several
years prior to the appearance of cognitive
symptoms. The examination of vascular
risk factors for AD and Aβ levels among
cognitively normal individuals may pro-
vide insight into the potentially pathologi-
cal processes that may predispose indi-
viduals to an increased risk. The
cognitively normal cohort with an en-
riched family history of AD-like dementia
may be a high-risk population for devel-
opment of this disease and an ideal group
for evaluation of vascular risk factors of
AD and blood Aβ levels. Therefore, in this
study, we examined the potential associa-
tion between serum Aβ1-40 and Aβ1-42 lev-
els and vascular risk factors among cogni-
tively normal first-degree relatives of
patients with AD or related dementia.
MATERIAL AND METHODS
Study Population and Data Collection
The Alzheimer’s Disease Antiinflam-
matory Prevention Trial (ADAPT) was a
multicenter trial funded by the National
Institutes of Health to test the effects of
nonsteroidal antiinflammatory drugs
(NSAIDs) on the prevention of AD. The
participants in ADAPT were selected
based on the presence of a first-degree
relative with AD-like dementia. The
study intervention (celecoxib, 200 mg
twice a day; naproxen sodium, 220 mg
twice a day; or placebo) was randomly
assigned to each participant. At eligibil-
ity determination a study-specific stan-
dard questionnaire was administered,
which included questions pertaining to
the presence of cardiovascular disease
and associated vascular risk factors.
Data were collected on history of angina,
congestive heart disease, occurrence and
number of strokes, and current and/or
past use of medications for hyperten-
sion, hypercholesterolemia, and dia-
betes. Vital signs, such as blood pressure
and weight, were also measured. To de-
termine eligibility a physical exam was
conducted by a medical doctor, and a
brief neuropsychological battery was ad-
ministered by trained psychometricians.
A similar questionnaire aimed at gather-
ing new occurrences of the above data
during the length of the trial was admin-
istered at each semiannual in-person
visit (physical exam and cognitive test-
ing was performed at each annual visit).
Blood samples were collected for safety
monitoring at these visits, which in-
cluded measurement (performed by
Covance) of serum creatinine, total
cholesterol, LDL, and high-density
lipoprotein (HDL). Additional informa-
tion on eligibility and methods is avail-
able at http://www.jhucct.com/adapt/
manall43.pdf.
For this ancillary study, 197 cognitively
normal participants (ADAPT subpopula-
tion) were recruited from the Tampa Bay
area and Sarasota (Florida site), and ad-
ditional blood samples were collected at
the semiannual visits to measure Aβ lev-
els. Within the ADAPT subpopulation,
we examined the association of Aβ with
total cholesterol, LDL, HDL, systolic
blood pressure (SBP), diastolic blood
pressure (DBP), serum creatinine, and
use of prescribed medications to treat
vascular risk factors. Self reports of cur-
rent use (at the time of the blood draw
for this ancillary study) of angiotensin-
converting enzyme inhibitors, angio-
tensin II receptor blockers, dihydro-
pyridines, and nondihydropyridine
calcium-channel blockers were combined
into one single binary variable as antihy-
pertensives use, and code was indicated
by 1 for yes. Similarly, current use of
statins was also coded as 1 into a sepa-
rate binary variable. Aβ levels were also
examined with the study treatment as-
signments and this was coded into a
single categorical variable for which pla-
cebo was coded as 0, celecoxib as 1, and
naproxen as 2.
Another cognitively normal group
(non-ADAPT) was used only for com-
parison of general demographics, hy-
pertension, hypercholesterolemia, dia-
betes, APOE genotypes, and serum Aβ
with the ADAPT subpopulation. This
non-ADAPT group consisted of 98 par-
ticipants recruited from the local retire-
ment centers in Tampa and Sarasota,
Florida. Family history data were avail-
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able for 82 of the non-ADAPT group,
and 37 of those had a positive family
history. For this non-ADAPT cohort,
history of past or present occurrence of
conditions such as hypertension, hyper-
cholesterolemia, diabetes, and cardio-
vascular diseases, and current use of
prescribed medications, was also col-
lected by self-report via answers to an
intake questionnaire. A mini–mental sta-
tus examination was administered to
determine cognitive status. In addition,
these individuals maintained indepen-
dent activities of daily living and were
free of active neurological illness, psy-
chiatric disorders, or other medical con-
ditions that would potentially interfere
with their cognitive performance. For
both study groups, past or present oc-
currence of hypertension, hypercholes-
terolemia, and diabetes was coded as 1
in separate binary variables.
Ethical Considerations
The Western Institutional Review
Board approved this study.
Sample Collection and Preparation
and Aβ Measurements
Venous blood was collected in serum
separator tubes (BD Diagnostics, Oxford,
UK), allowed to clot for 30 min, cen-
trifuged for 15 min at 1380g, aliquoted,
and immediately frozen at –80°C. The Aβ
content of serum was determined, ac-
cording to manufacturer’s instructions,
by use of the human Aβ1-40 and high-
sensitivity Aβ1-42 ELISA kits (Invitrogen,
Carlsbad, CA, USA). As per the manu-
facturer, for Aβ1-40, the interassay coeffi-
cient of variation (CV) was ≤2.8% and
the intraassay CV was about 4%. For 
Aβ1-42 both interassay and intraassay CVs
were reported to be about 10%. The de-
tection limits for Aβ1-40 and Aβ1-42 were
approximately 8 pg/mL and 1 pg/mL,
respectively. We were unable to obtain
readings for Aβ on 18 individuals.
APOE Genotyping
We extracted DNA from whole blood
by using Pure Gene Kits (Gentra Sys-
tems, Minneapolis, MN, USA) and per-
formed APOE genotyping by using pre-
viously established methods (22).
Statistical Analyses
Data were analyzed with a cross-
sectional design. All statistical analyses
were performed using Stata software
(version 9.0 and 9.2). Group differences
were determined with either the Student
t test or χ2 statistics, based on the type of
variable. Upon evaluation of normality,
Aβ1-42, and Aβ1-42/Aβ1-40 ratios were de-
termined to be positively skewed. There-
fore we used the Mann-Whitney test to
determine group differences and the
Spearman′s correlation coefficient (rho)
to assess possible linear associations. The
means and standard deviations were
used to summarize symmetric continu-
ous variables; and the medians and in-
terquartile ranges (IQR) were used to
summarize data with nonsymmetric dis-
tributions. Regression modeling was em-
ployed to examine the multivariate rela-
tionship of vascular risk factors with
Aβ1-40, and given the lack of normality of
the Aβ1-42 data, the bootstrap resampling
approach was used to estimate standard
errors. These analyses were exploratory;
no adjustments were made for multiple
testing, and therefore the results are in-
terpreted cautiously.
RESULTS
Difference in hypertension, diabetes,
hypercholesterolemia, APOE ε4 carrier
status, and basic demographics were
evaluated between the ADAPT subpopu-
lation and the non-ADAPT group. Both
groups were volunteer based and similar
in age, sex, and ethnicity (Table 1). Com-
parison of Aβ1-40 and Aβ1-42 levels be-
tween these two groups revealed that
Aβ1-40, Aβ1-42, and Aβ1-42/Aβ1-40 ratios
were higher in the ADAPT subpopula-
tion than the non-ADAPT group (Table 1).
Age was associated with Aβ1-40 in both of
these groups; a correction for age was
applied, and the difference in Aβ1-40 was
no longer significant (Table 1). Age was
not associated with Aβ1-42, and sex was
not associated with Aβ1-42 or Aβ1-40 levels.
Though not significant, the proportion of
individuals with APOE ε4 genotypes, hy-
pertension, and diabetes was higher in
the ADAPT subpopulation compared
with non-ADAPT (Table 1). Frequency of
individuals with hypercholesterolemia
was significantly higher in the ADAPT
subpopulation compared with non-
ADAPT (Table 1).
The following analyses were per-
formed only within the ADAPT subpop-
ulation to determine possible relation-
ships between the use of medications to
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Table 1. Comparison of the non-ADAPT and ADAPT subpopulations.a
Non-ADAPT ADAPT subpopulation 
subjects (n = 98) subjects (n = 197) P-value
n (%)
Female (%) 54 (55) 91 (47) 0.17
White (%) 96 (98) 193 (98) 0.68
Diabetes (%) 8 (8) 19 (10) 0.74
Hypertension (%) 55 (57) 122 (62) 0.39
Hypercholesterolemia (%) 38 (39) 103 (52) 0.03
APOE ε4 allele (%) 27 (28) 63 (32) 0.44
Mean ± SD
Age (years) 75.2 ± 8.21 76.8 ± 3.93 0.07
Serum Aβ1-40 (pg/mL)b 132.6 ± 49.65 146.3 ± 54.59 0.13
Median [IQR]
Serum Aβ1-42 (pg/mL) 4.9 [2.9, 9.1] 12.0 [5.0, 22.9] P < 0.001
Serum Aβ1-42/Aβ1-40 0.04 [0.02, 0.07] 0.08 [0.05, 0.15] P < 0.001
aAβ1-40 below detection limit for 9 individuals and Aβ1-42 below detection limit for 18
individuals.
bDifferences in Aβ1-40 between the two groups are corrected for age.
treat vascular risk factors, blood pres-
sure, lipid levels, serum creatinine, and
assignment of the study medications
with Aβ1-42 and Aβ1-40 (Table 2). No dif-
ferences in Aβ1-40 and Aβ1-42 between the
placebo, celecoxib, or naproxen were de-
tected, although median Aβ1-42 levels
were slightly lower in the celecoxib
group compared with the other groups
(placebo, median 14.61 pg/mL [IQR
6.49–23.24 pg/mL]; celecoxib, median
9.73 pg/mL [IQR 5.34–18.13 pg/mL];
naproxen, median 11.14 pg/mL [IQR
4.67–24.16 pg/mL]). Aβ1-40 was positively
associated with Aβ1-42 (rho = 0.314, 
P <0.001), SBP (r = 0.150, P = 0.035), age 
(r = 0.212, P = 0.003), and serum creati-
nine (r = 0.361, P <0.001). Serum creati-
nine was associated with SBP (r = 0.216,
P = 0.002). No correlation was observed
for either Aβ1-40 or Aβ1-42 with weight (r =
0.037, P = 0.60 and rho = 0.022, P = 0.76
respectively). No relationship between
SBP and Aβ1-42 (rho = 0.007, P = 0.93) or
between diastolic blood pressure with
Aβ1-40 or Aβ1-42 was observed (r = –0.004,
P = 0.96 and rho = 0.01, P = 0.88, respec-
tively). Aβ1-40 levels were found to be
higher among users of antihypertensives
compared with nonusers (155.15 pg/mL ±
52.70 SD and 141.1 pg/mL ± 56.95 SD,
respectively).
Multivariate regression analyses re-
vealed a linear relationship of Aβ1-40 with
age, serum creatinine, and hypertension
medication use (Table 3). A marginal
negative interactive association was ob-
served between SBP, use of antihyperten-
sives, and Aβ1-40 levels (β = –1.28, 95% CI
[–2.57 to 0.014], P = 0.052, Table 3). Strati-
fication of the relationship between SBP
and Aβ1-40 by use of antihypertensives
showed a positive correlation among the
nonusers (r = 0.25, P = 0.006), but no
such correlation was evident among
users (r = –0.06, P = 0.61)
As expected, significantly lower cho-
lesterol and LDL levels were observed
among statin users, and although 5%
higher HDL was also observed, these dif-
ferences were not significant (data not
shown). An association was observed be-
tween statin use and Aβ1-42 (β = 6.93, bias
corrected 95% CI [1.26–13.59], P = 0.02,
Figure 1). In this model, no adjustment
was required for age, serum creatinine,
or blood pressure because these variables
were not associated with Aβ1-42. Given
the impact of statins on cholesterol levels
and the observed association of Aβ1-42
levels with statin use, we stratified the
study sample by statin use to determine
the relationship of Aβ1-42 with lipid lev-
els. A positive correlation of HDL levels
was observed with Aβ1-42 in nonusers
(rho = 0.309, P = 0.02), but no such asso-
ciation was observed in the statin users
(rho = –0.091, P > 0.05). No relationship
of Aβ1-42 with LDL and total cholesterol
was observed. We also examined the po-
tential influence of the ε4 allele of APOE
on Aβ1-42 levels. APOE genotypes were
determined to be in Hardy-Weinberg
equilibrium. No statistically significant
differences with APOE genotype were
observed, although median Aβ1-42 levels
were generally lower in the ε4 carriers
(non–ε4 carriers, median 12.14 pg/mL
[IQR 4.85–24.16 pg/mL]; ε4 heterozy-
gotes, median 10.56 pg/mL [IQR
6.49–22.53 pg/mL]; and ε4 homogy-
gotes, median 10.11 pg/mL, [IQR
3.72–16.90 pg/mL]).
DISCUSSION
Findings reported here show signifi-
cantly higher Aβ1-42 among the ADAPT
subpopulation (selected based on the
presence of first-degree relatives with
AD) compared with the non-ADAPT
group. These findings are consistent with
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Table 2. Vascular factors and medication
use in the ADAPT subpopulation.a
Baseline measurements Mean ± SD
SBP (mmHg) 133.47 ± 11.65
DBP (mmHg) 75.30 ± 6.50
Creatinine (mg/dL) 0.95 ± 0.22
Cholesterol (mg/dL) 191.92 ± 39.34
LDL (mg/dL) 105.27 ± 34.07
HDL (mg/dL) 48.70 ± 12.51
Medication use (yes) Number (%)
Dihydropyridine 18 (9)
Nondihydropyridine 2 (1)
Angiotensin-converting enzyme 46 (23)
inhibitor
Angiotensin II receptor blockers 21 (11)
Statin 84 (43)
Placebo 83 (42)
Celecoxib 52 (26)
Naproxen 62 (32)
aSBP and DBP were unavailable for one
individual,and creatinine was unavailable
for two individuals.Total cholesterol was
available for 195 subjects,HDL was available
for 102 subjects,and LDL was available for
100 subjects.
Table 3. Predictors of Aβ1-40 levels among the ADAPT subpopulation
Predictorsa β [95% CI] P-value
Age (1-year increase) 2.41 [0.57 to 4.26] 0.011
Creatinine (mg/dL) 81.52 [47.29 to 115.75] <0.001
Antihypertensive use (yes) 176.43 [1.36 to 351.50] 0.048
SBP (mmHg) 0.75 [–0.04 to 1.54] 0.063
Antihypertensive use × SPP –1.28 [–2.57 to 0.014] 0.052
aAnalyses were performed using multivariate regression modeling, in which age, creatinine,
antihypertensive use, SBP, and the interactive term were in the same linear model.
Figure 1. Median Aβ1-42 levels among
statin nonusers is 12.03 pg/mL (interquartile
range [IQR] 5.90–21.75 pg/mL), and me-
dian among statin users is 11.75 pg/mL
(IQR 5.52–28.76 pg/mL).
those of Ertekin-Taner and colleagues
showing elevated Aβ1-42 in another fam-
ily history–enriched cohort (9). Although
several studies have shown differences
between APOE ε4 carriers and noncarri-
ers with cognitive decline and disease
progression, a clear association of APOE
ε4 status with plasma Aβ has not yet
been demonstrated (23,24). Therefore, we
speculate that elevated Aβ1-42 among
first-degree relatives of sporadic AD pa-
tients may be indicative of increased Aβ
production due to genetic and/or other
risk factors.
Alteration in cholesterol levels and
homeostasis have been associated with
AD pathology (18,19), although possible
reduction in AD risk with statin use re-
mains controversial owing to the incon-
sistency of past findings (25). Further-
more, data from several recent studies,
including data from another ADAPT an-
cillary study, suggest lowered risk of AD
among statin users (26–28). However,
plasma Aβ remains unaltered after statin
treatment among AD or hypercholester-
olemia patients (29). A significant in-
crease in blood Aβ1-42 levels among statin
users in the ADAPT subpopulation was
observed and is similar to the findings
among males from a non–family-based
sample (30). Because individuals with
hypercholesterolemia are likely to be
statin users and also at increased risk for
AD, it is possible that higher Aβ1-42
among statin users may be coincidental
and just a reflection of this increased risk
of AD. However, longitudinal studies are
required to determine the consequence of
statin therapy on Aβ1-42 levels as it relates
to AD risk.
Several studies show that HDL in
human serum binds to Aβ via interaction
with apoA, apoJ, and apoC-III (31–34).
We found a significant positive correla-
tion of HDL levels with Aβ1-42 levels
among statin nonusers. Similarly, a pre-
vious study evaluating plasma Aβ1-42
among 18 healthy individuals found a
correlation between HDL and Aβ1-42 (35).
However, Mayeux and colleagues re-
ported an association of HDL with Aβ1-40
instead (2). These discrepancies may be
due to differences in population charac-
teristics or disease stages, but neverthe-
less suggest a probable association of
HDL with peripheral Aβ. Thus, these
findings suggest that a positive associa-
tion of Aβ1-42 with HDL may be due to its
clearance from the brain. Longitudinal
follow-up of this ADAPT subpopulation
is required to fully understand this asso-
ciation between HDL and Aβ1-42.
As with Blasko and colleagues, we
observed no association of Aβ1-42 with
the use of anti-hypertensives (30). In-
stead, elevated Aβ1-40 among the
ADAPT subpopulation on antihyperten-
sives and a negative interaction between
use of antihypertensives and SBP on
Aβ1-40 levels were detected. These find-
ings may suggest that among individu-
als not on antihypertensives, association
of SBP and Aβ1-40 levels may be indica-
tive of increased risk for AD and may
reflect increased Aβ1-40 production.
However, among individuals who use
antihypertensives, the observed associa-
tion with Aβ1-40 may indicate increased
clearance from the brain, but further
studies are required to fully understand
the mechanisms behind increased pro-
duction versus increased clearance with
respect to blood Aβ measurements in
sporadic AD.
Consistent with other reported studies,
our study showed a significant positive
association between Aβ1-40 and serum
creatinine (2,36). The cause of this rela-
tionship is still unclear, and its examina-
tion may be helpful in furthering our un-
derstanding of AD pathology.
Naproxen, a nonselective cyclooxyge-
nase inhibitor, has been shown to prefer-
entially lower Aβ1-42 in vitro (37). Because
the ADAPT cohort received NSAIDs, we
evaluated the potential effect of these in-
terventions on both Aβ1-40 and Aβ1-42 in
the ADAPT subpopulation and found no
difference between the effects of placebo,
celecoxib, and naproxen treatments on
Aβ1-40 and Aβ1-42 levels. Although data
from a pooled study of six different co-
horts suggest that reduced incidence of
AD is associated with NSAID use, there
was no apparent advantage attributed to
Aβ-lowering compounds (38). More re-
cently, a disease-modifying clinical trial
for AD using R-flurbiprofen, a selective
Aβ1-42-lowering NSAID, failed to show
any efficacy (39). However, recent find-
ings from the main ADAPT cohort show
reduced incidence of AD in the naproxen
group compared with the groups receiv-
ing celecoxib or placebo (40). Therefore,
further investigation is required to deter-
mine the full impact of NSAIDs on AD
pathogenesis and whether Aβ-lowering
NSAID compounds have any effect on
peripheral Aβ levels.
There is a growing consensus that
changes in blood Aβ levels parallel AD
onset and progression, although these
findings remain discrepant with respect
to specific species, that is, Aβ1-42 or Aβ1-40
(2–6). Despite this discrepancy, evidence
is now emerging in favor of the more
pathologic form, Aβ1-42, being elevated at
the stage of mild cognitive impairment
or an even earlier prodromal stage of
AD, possibly owing to increased produc-
tion (2,5,7). These findings suggest that
increased risk of AD associated with
family history may be mediated in part
through the enrichment of individuals
with vascular risk factors and may be re-
flective of presymptomatic AD pathol-
ogy. It remains to be determined, how-
ever, whether association of Aβ with
medication used to treat vascular risk
factors is indicative of prevention or
amelioration of AD. Nonetheless, this ex-
ploratory study, which provides baseline
data, and longitudinal evaluation of pe-
ripheral Aβ will provide a better under-
standing of the significance of this asso-
ciation in AD etiology.
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